EQUILLIUM INC
EQNASDAQTrading Snapshot
- Day Range
- $1.61 – $1.63
- 52-Week Range
- $0.76 – $3.54
- Volume
- $7.77B
- Avg Volume
- $10.30B
- Shares Outstanding
- 63.2M
- Next Earnings
- Oct 27, 2026
Fundamentals Snapshot
- Annual Revenue
- $40M
- Last Q Revenue
- $10M
- P/E Ratio
- —
- P/S Ratio
- 2.6x
- EPS (TTM)
- $-0.32
- Dividend Yield
- —
- Dilution (1yr)
- +159.9%
Why Investors Own EQ
- ✓High-growth profile — revenue up +43.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 38% gross margin and 25% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
EQUILLIUM INC
EQ
StockOtter · stockotter.spaceAbout EQUILLIUM INC
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Equillium Announces Poster Presentations at the 7th International AHR Conference
New preclinical data further characterize EQ504's effects on epithelial barrier repair and immune regulation New preclinical data further characterize EQ504's effects on epithelial barrier repair and immune regulation
Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504
Equillium (NASDAQ: EQ) Chief Scientific Officer Stephen Connelly outlined the company's plans to advance its lead programs, including an oral aryl hydrocarbon receptor, or AhR, modulator for ulcerative colitis and an ora
Equillium to Participate in Stifel's 2026 Virtual Immunology and Inflammation Forum
LA JOLLA, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that manageme
EQ Resources to take 10% stake in Nevada tungsten project JV with Elmet, Blue Moon
Australian miner EQ Resources said on Tuesday it would take a 10% stake in a joint venture with Nasdaq-listed Elmet Group and Blue Moon Metals to restart the Springer tungsten project in Nevada.
Equillium to Participate in Upcoming Investor Conferences
LA JOLLA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that manageme
Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Phase 1 proof-of-mechanism study of EQ504 initiation expected in Q4 2026, with data expected approximately six months thereafter Cash and cash equivalents of $57.2 million expected to fund operations into 2029 LA JOLLA,